Literature DB >> 31845423

Leptin, adiponectin, and their ratio as markers of insulin resistance and cardiometabolic risk in childhood obesity.

Christine Frithioff-Bøjsøe1,2, Morten A V Lund1,3, Ulrik Lausten-Thomsen4, Paula L Hedley5, Oluf Pedersen2, Michael Christiansen3,5, Jennifer L Baker2,6, Torben Hansen2,7, Jens-Christian Holm1,2,8.   

Abstract

BACKGROUND: It is imperative to develop markers for risk stratification and detection of cardiometabolic comorbidities in children with obesity. The adipokines leptin and adiponectin are both involved in fat mass regulation and the development of obesity-related disorders; furthermore, their ratio (leptin/adiponectin ratio) is suggested to be associated with insulin resistance and cardiometabolic risk.
OBJECTIVE: To evaluate associations between fasting serum concentrations of the adipokines (total leptin and adiponectin as well as the L/A ratio) and cardiometabolic comorbidities in children with overweight/obesity.
METHODS: A total of 2258 children with overweight/obesity or normal weight aged 6 to 18 years were studied. Differences in anthropometrics and adipokine concentrations were tested using Wilcoxon rank-sum test. Associations between the adipokines and cardiometabolic risk were tested using Spearman's correlation and logistic regression, adjusted for age and body mass index SD score (BMI-SDS).
RESULTS: Compared to normal weight children; children with overweight/obesity exhibited higher leptin concentrations, lower adiponectin concentrations, and higher L/A ratios. After adjusting for age and degree of obesity, girls with overweight/obesity in the upper quartile range for the L/A ratio, when compared with girls in the lower quartile range, were more likely to have insulin resistance (odds ratio [OR]: 7.78 [95% confidence interval [CI], 3.78-16.65]), dysglycemia (OR: 3.08 [95% CI, 1.35-7.31]), and dyslipidemia (OR: 2.53 [95% CI, 1.18-5.59]); while boys were more likely to have insulin resistance (OR: 4.45 [95% CI, 2.03-10.10]).
CONCLUSIONS: Independent of the degree of obesity, leptin, adiponectin, and the L/A ratio were associated with insulin resistance and other cardiometabolic comorbidities in children with overweight/obesity, but the L/A ratio exhibited stronger associations than the respective adipokines.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  adiponectin; biomarkers; insulin resistance; leptin; pediatric obesity

Mesh:

Substances:

Year:  2019        PMID: 31845423     DOI: 10.1111/pedi.12964

Source DB:  PubMed          Journal:  Pediatr Diabetes        ISSN: 1399-543X            Impact factor:   4.866


  20 in total

1.  The dietary inflammatory index is associated with anti- and pro-inflammatory adipokines in Brazilian schoolchildren.

Authors:  Lara Gomes Suhett; H H M Hermsdorff; Sarah Aparecida Vieira Ribeiro; Mariana De Santis Filgueiras; Nitin Shivappa; James R Hébert; Juliana Farias de Novaes
Journal:  Eur J Nutr       Date:  2021-02-11       Impact factor: 5.614

2.  Pro- and anti-inflammatory adipokines are associated with cardiometabolic risk markers in Brazilian schoolchildren.

Authors:  Mariana De Santis Filgueiras; Milene Cristine Pessoa; Josefina Bressan; Fernanda Martins de Albuquerque; Lara Gomes Suhett; Mariane Alves Silva; Juliana Farias de Novaes
Journal:  Eur J Pediatr       Date:  2021-04-09       Impact factor: 3.183

3.  Gestational and childhood exposure to per- and polyfluoroalkyl substances and cardiometabolic risk at age 12 years.

Authors:  Nan Li; Yun Liu; George D Papandonatos; Antonia M Calafat; Charles B Eaton; Karl T Kelsey; Kim M Cecil; Heidi J Kalkwarf; Kimberly Yolton; Bruce P Lanphear; Aimin Chen; Joseph M Braun
Journal:  Environ Int       Date:  2021-01-06       Impact factor: 9.621

4.  Circulating inflammatory biomarkers in adolescents: evidence of interactions between chronic pain and obesity.

Authors:  Keri R Hainsworth; Pippa M Simpson; Hershel Raff; Mitchell H Grayson; Liyun Zhang; Steven J Weisman
Journal:  Pain Rep       Date:  2021-04-01

Review 5.  Effect of Leptin on Chronic Inflammatory Disorders: Insights to Therapeutic Target to Prevent Further Cardiovascular Complication.

Authors:  Gashaw Dessie; Birhanu Ayelign; Yonas Akalu; Tewodros Shibabaw; Meseret Derbew Molla
Journal:  Diabetes Metab Syndr Obes       Date:  2021-07-17       Impact factor: 3.168

6.  Degree of Agreement Between Infant Serum and Salivary Concentration of Leptin and Adiponectin and Its Association With Infants' Feeding.

Authors:  Ana M Linares; Mary Kay Rayens; Jennifer S Moylan; Craig S Miller
Journal:  Biol Res Nurs       Date:  2020-11-28       Impact factor: 2.318

7.  Plasma Adipokines Profile in Prepubertal Children with a History of Prematurity or Extrauterine Growth Restriction.

Authors:  María Dolores Ordóñez-Díaz; Mercedes Gil-Campos; Katherine Flores-Rojas; María Carmen Muñoz-Villanueva; Concepción María Aguilera-García; María Jose de la Torre-Aguilar; Juan Luis Pérez-Navero
Journal:  Nutrients       Date:  2020-04-24       Impact factor: 5.717

8.  Serum concentration of asprosin in new-onset type 2 diabetes.

Authors:  Shakiba Naiemian; Mohsen Naeemipour; Mehdi Zarei; Moslem Lari Najafi; Ali Gohari; Mohammad Reza Behroozikhah; Hafez Heydari; Mohammad Miri
Journal:  Diabetol Metab Syndr       Date:  2020-07-23       Impact factor: 3.320

9.  Elevated Serum Level of Cytokeratin 18 M65ED Is an Independent Indicator of Cardiometabolic Disorders.

Authors:  Lingling Qian; Lei Zhang; Liang Wu; Jing Zhang; Qichen Fang; Xuhong Hou; Qiongmei Gao; Huating Li; Weiping Jia
Journal:  J Diabetes Res       Date:  2020-03-31       Impact factor: 4.011

Review 10.  Adipokines, Myokines, and Hepatokines: Crosstalk and Metabolic Repercussions.

Authors:  Ana Rita de Oliveira Dos Santos; Bárbara de Oliveira Zanuso; Vitor Fernando Bordin Miola; Sandra Maria Barbalho; Patrícia C Santos Bueno; Uri Adrian Prync Flato; Claudia Rucco P Detregiachi; Daniela Vieira Buchaim; Rogério Leone Buchaim; Ricardo José Tofano; Claudemir Gregório Mendes; Viviane Alessandra Capelluppi Tofano; Jesselina F Dos Santos Haber
Journal:  Int J Mol Sci       Date:  2021-03-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.